Dr. Reddy’s in licenses biosimilar for J&J’s multiple myeloma therapy
Dr. Reddy's (RDY) partners with Shanghai Henlius Biotech to develop and market biosimilar versions of J&J's (JNJ) multiple ...
Hosted on MSN1d
Dr Reddy’s and Shanghai Henlius sign agreement for HLX15
Dr Reddy's Laboratories has signed a licence agreement with Shanghai Henlius Biotech to develop and commercialise HLX15, a ...
Business Wire2d
Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe
HLX15 is being developed as a biosimilar of Darzalex® & Darzalex Faspro®*, which are indicated for the treatment of multiple myeloma. The agreement combines Dr. Reddy’s global commercial ...
Pharmabiz2d
Dr Reddy’s inks pact with Henlius to commercialize HLX1, a biosimilar candidate in US & Europe
Dr Reddy’s inks pact with Henlius to commercialize HLX1, a biosimilar candidate in US & Europe: Our Bureau, Bengaluru Thursday, February 6, 2025, 17:20 Hrs [IST] Dr Reddy’s La ...
Mena FN16d
Darzalex Faspro Global Market Report 2025: Growth, Trends, And Forecasts
What Does the Darzalex Faspro Market Look Like? The darzalex faspro market witnessed significant growth in recent years with recorded XX in historic compound annual growth rate HCAGR. Within a ...
pharmaphorum21d
J&J bids to add smouldering myeloma to Darzalex label
The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 antibody, which can be given as a physician-administered subcutaneous ...
Dr. Reddy’s, Shanghai Henlius Biotech ink $131.6 million cancer drug deal
Dr. Reddy’s to develop and commercialize biosimilar candidate for Johnson & Johnson’s Darzalex drugs with Shanghai Henlius Biotech.
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
Company AnnouncementNet sales of DARZALEX® in 2024 totaled USD 11,670 millionGenmab receives royalties on worldwide net sales from Johnson & ...
Yahoo Finance18d
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody ...